Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GoTIL-01: Autologous Tumor Infiltrating Lymphocytes in Metastatic Melanoma
NCT07183852Phase 1Not yet recruiting
- Sponsor
- Region Västra Götaland
- Start
- Jan 2027
- Primary completion
- Mar 2028
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
01
Overview
Phase 1, open-label trial of MDA-TIL in Uveal melanoma (UM) and cutaneous melanoma (CM) (2 cohorts), sponsored by Region Västra Götaland. Primary endpoint: Incidence and severity of adverse events at 5 years. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
MDA-TIL
03
Conditions
Uveal melanoma (UM)cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT07183852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07183852.